Literature DB >> 28442369

Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABAA receptors.

J M Witkin1, R Cerne2, M Wakulchik2, J S2, S D Gleason2, T M Jones2, G Li3, L A Arnold3, J-X Li4, J M Schkeryantz2, K R Methuku3, J M Cook3, M M Poe3.   

Abstract

Positive allosteric modulators of GABAA receptors transduce a host of beneficial effects including anxiolytic actions. We have recently shown that bioavailability and anxiolytic-like activity can be improved by eliminating the ester functionality in imidazo[1,5-a][1,4]diazepines. In the present series of experiments, we further substantiate the value of heterocyle replacement of the ester for potential treatment of anxiety. None of three esters was active in a Vogel conflict test in rats that detects anxiolytic drugs like diazepam. Compounds 7 and 8, ester bioisosters, were selective for alpha 2 and 3 over alpha 1-containing GABAA receptors but also had modest efficacy at GABAA alpha 5-containing receptors. Compound 7 was efficacious and potent in this anxiolytic-detecting assay without affecting non-punished responding. The efficacies of the esters and of compound 7 were predicted from their efficacies as anticonvulsants against the GABAA antagonist pentylenetetrazole (PTZ). In contrast, the related structural analog, compound 8, did not produce anxiolytic-like effects in rats despite anticonvulsant efficacy. These data thus support the following conclusions: 1) ancillary pharmacological actions of compound 8 might be responsible for its lack of anxiolytic-like efficacy despite its efficacy as an anticonvulsant 2) esters of imidazo[1,5-a][1,4]diazepines do not demonstrate anxiolytic-like effects in rats due to their low bioavailability and 3) replacement of the ester function with suitable heterocycles markedly improves bioavailability and engenders molecules with the opportunity to have potent and efficacious effects in vivo that correspond to human anxiolytic actions.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28442369      PMCID: PMC5519285          DOI: 10.1016/j.pbb.2017.04.009

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  30 in total

1.  Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure.

Authors:  Bradford D Fischer; Stephanie C Licata; Rahul V Edwankar; Zhi-Jian Wang; Shengming Huang; Xiaohui He; Jianming Yu; Hao Zhou; Edward M Johnson; James M Cook; Roman Furtmüller; Joachim Ramerstorfer; Werner Sieghart; Bryan L Roth; Samarpan Majumder; James K Rowlett
Journal:  Neuropharmacology       Date:  2010-08-18       Impact factor: 5.250

Review 2.  Benzodiazepines and anxiety disorders: a review for the practicing physician.

Authors:  Eric Michael Kaplan; Robert L DuPont
Journal:  Curr Med Res Opin       Date:  2005-06       Impact factor: 2.580

3.  NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects.

Authors:  Rob G J A Zuiker; Xia Chen; Ole Østerberg; Naheed R Mirza; Pierandrea Muglia; Marieke de Kam; Erica S Klaassen; Joop M A van Gerven
Journal:  J Psychopharmacol       Date:  2015-12-10       Impact factor: 4.153

4.  Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist.

Authors:  J R Atack; D J Hallett; S Tye; K A Wafford; C Ryan; S M Sanabria-Bohórquez; Wai-Si Eng; R E Gibson; H D Burns; G R Dawson; R W Carling; L J Street; A Pike; I De Lepeleire; K Van Laere; G Bormans; J N de Hoon; A Van Hecken; R M McKernan; M G Murphy; R J Hargreaves
Journal:  J Psychopharmacol       Date:  2010-02-15       Impact factor: 4.153

Review 5.  GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics.

Authors:  John R Atack
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

6.  Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator.

Authors:  A Lippa; P Czobor; J Stark; B Beer; E Kostakis; M Gravielle; S Bandyopadhyay; S J Russek; T T Gibbs; D H Farb; P Skolnick
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

7.  Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.

Authors:  Nancy A Ator; John R Atack; Richard J Hargreaves; H Donald Burns; Gerard R Dawson
Journal:  J Pharmacol Exp Ther       Date:  2009-09-29       Impact factor: 4.030

Review 8.  Anxioselective anxiolytics: on a quest for the Holy Grail.

Authors:  Phil Skolnick
Journal:  Trends Pharmacol Sci       Date:  2012-09-14       Impact factor: 14.819

Review 9.  Receptors for the age of anxiety: pharmacology of the benzodiazepines.

Authors:  J F Tallman; S M Paul; P Skolnick; D W Gallager
Journal:  Science       Date:  1980-01-18       Impact factor: 47.728

10.  Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype.

Authors:  William T Ralvenius; Dietmar Benke; Mario A Acuña; Uwe Rudolph; Hanns Ulrich Zeilhofer
Journal:  Nat Commun       Date:  2015-04-13       Impact factor: 14.919

View more
  5 in total

1.  The Positive Allosteric Modulator of α2/3-Containing GABAA Receptors, KRM-II-81, Is Active in Pharmaco-Resistant Models of Epilepsy and Reduces Hyperexcitability after Traumatic Brain Injury.

Authors:  Jeffrey M Witkin; Guanguan Li; Lalit K Golani; Wenhui Xiong; Jodi L Smith; Xingjie Ping; Farjana Rashid; Rajwana Jahan; Rok Cerne; James M Cook; Xiaoming Jin
Journal:  J Pharmacol Exp Ther       Date:  2019-11-06       Impact factor: 4.030

2.  The α2,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats.

Authors:  J M Witkin; R Cerne; P G Davis; K B Freeman; J M do Carmo; J K Rowlett; K R Methuku; A Okun; S D Gleason; X Li; M J Krambis; M Poe; G Li; J M Schkeryantz; R Jahan; L Yang; W Guo; L K Golani; W H Anderson; J T Catlow; T M Jones; F Porreca; J L Smith; K L Knopp; J M Cook
Journal:  Pharmacol Biochem Behav       Date:  2019-02-27       Impact factor: 3.533

3.  Improved Synthesis of Anxiolytic, Anticonvulsant and Antinociceptive α2/α3-GABA(A)ergic Receptor Subtype Selective Ligands as Promising Agents to Treat Anxiety, Epilepsy, as well as Neuropathic Pain.

Authors:  Guanguan Li; Lalit K Golani; Rajwana Jahan; Farjana Rashid; James M Cook
Journal:  Synthesis (Stuttg)       Date:  2018-10       Impact factor: 3.157

4.  8-Substituted Triazolobenzodiazepines: In Vitro and In Vivo Pharmacology in Relation to Structural Docking at the α1 Subunit-Containing GABAA Receptor.

Authors:  Lalit K Golani; Donna M Platt; Daniela Rüedi-Bettschen; Chitra Edwanker; Shenming Huang; Michael M Poe; Roman Furtmüller; Werner Sieghart; James M Cook; James K Rowlett
Journal:  Front Pharmacol       Date:  2021-04-20       Impact factor: 5.810

5.  Hydrochloride Salt of the GABAkine KRM-II-81.

Authors:  Md Yeunus Mian; Branka Divović; Dishary Sharmin; Kamal P Pandey; Lalit K Golani; V V N Phani Babu Tiruveedhula; Rok Cerne; Jodi L Smith; Xingjie Ping; Xiaoming Jin; Gregory H Imler; Jeffrey R Deschamps; Arnold Lippa; James M Cook; Miroslav M Savić; James Rowlett; Jeffrey M Witkin
Journal:  ACS Omega       Date:  2022-07-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.